Protein kinase C isoforms as therapeutic targets in nervous system disease states

Pharmacological Research

Volumn 44, Issue 5, 2001, Pages 353-361

  Battaini, Fiorenzo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Activators; Inhibitors; Isozymes; Neuronal pathologies; Phosphorylation; Protein kinase C; RACK

Indexed keywords

ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; DIACYLGLYCEROL; ISIS 3521; ISOENZYME; LITHIUM; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PHOSPHATIDYLSERINE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; STAUROSPORINE DERIVATIVE; SYNTHETIC PEPTIDE;

ALZHEIMER DISEASE; AMNESIA; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL MODEL; BRAIN INJURY; BRAIN ISCHEMIA; CLINICAL TRIAL; COMPULSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG INDUCED DISEASE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DISEASE; NERVE CELL CULTURE; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; NONHUMAN; OBSESSION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RAT; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 0035204621     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2001.0893     Document Type: Article

References (88)

1. Protein kinase C family and lipid mediators for transmembrane signaling and cell regulation
2. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissue I. Purification and characterization of an active enzyme from bovine cerebellum
3. Unsaturated diacylglycerol as a possible messenger for the activation of calcium activated phospholipid dependent protein kinase system
4. Isozymic forms of rat brain calcium activated and phospholipid dependent protein kinase
5. PKCν a new member of the protein kinase C family, composes a fourth subfamily with PKCμ
6. Rapid protein kinase D translocation in response to G protein-coupled receptor activation: Dependence on PKC
7. Simultaneous visualization of the translocation of protein kinase Cα-green fluorescent protein hybrids and intracellular calcium concentrations
8. Direct visualization of the translocation of the γ -subspecies of protein kinase C in living cells using fusion proteins with green fluorescent protein
9. Spatial temporal patterning of metabotropic glutamate receptor mediated inositol 1,4,5 triphosphate, calcium, and PKC oscillations: Protein kinase C-dependent receptor phosphorylation is not required
10. Pharmacological modulation of protein kinase C isozymes: The role of RACKs and subcellular localization
11. Multiple pathways control protein kinase C phosphorylation
12. Regulation of protein kinase C
13. Protein kinase C isozymes and the regulation of diverse cell responses
14. Signaling through protein kinase C
15. Phosphorylation sites of protein kinase C delta in H202-treated ceils and its activation by tyrosine kinase in vitro
16. Biosynthesis and posttranslational modification of protein kinase C in human breast cancer cells
17. Modulation of protein kinase C in antitumor treatment
18. Direct activation of calcium-activated phospholipiddependent protein kinase by tumor promoting phorbol esters
19. Protein kinase C and myocardial biology and function
20. T cell signal transduction and the role of PKC
21. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
22. Protein kinase C beta inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes
23. Protein kinase C in the treatment of disease: Signal transduction pathways, inhibitors, and agents in development
24. The protein kinase C family for neuronal signaling
25. Cognitive neuropharmacology: New perspectives for the pharmacology of cognition
26. How PKC activation protects nerve cells from oxidative stress-induced cell death
27. Protein serine/threonine kinase (PKA, PKC, CaMKII) involved in ischemic brain pathology
28. Protein kinase C expression and activity in the human brain after ischemic stroke
29. Alterations in brain protein kinase C after experimental brain injury
30. Superoxide generation links protein kinase C activation to impaired ATP-sensitive K+ channel function after brain injury
31. Improving the outcome of severe head injury with the oxygen radical scavenger polyethylene glycolconjugated superoxide dismutase: A phase II trial
32. Novel pharmacologic strategies in the treatment of experimental traumatic brain injury: 1998
33. Pharmacological drug treatment of Alzheimer's disease: The cholinergic hypothesis revisited
34. Changes in protein kinases in brain aging and Alzheimer's disease
35. Calcium-dependent and independent protein kinase C changes in the brains of patients with Alzheimer's disease
36. Assessment of protein kinase C mRNA levels in Alzheimer's disease brains
37. Attenuated protein kinase C activity and translocation in Alzheimer's disease brain
38. Protein kinase C activity and protein levels in Alzheimer's disease
39. Loss of inositol 1,4,5 triphosphate receptor sites and decreased PKC levels correlate with staging of Alzheimer's disease neurofibrillary pathology
40. The role of anchoring protein RACK1 in PKC activation in the aging rat brain
41. Protein kinase C anchoring deficit in postmortem brains of Alzheimer's disease patients
42. Cloning of an intracellular receptor for PKC: A homolog of the β subunit of G proteins
43. Coordinated movement of RACK1 with activated βIIPKC
44. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging
45. Intracellular receptors for activated C-kinase in the postmortem human brain: No alteration in Alzheimer's disease
46. Age-related alteration of PKC, a key enzyme in memory processes: Physiological and pathological examples
47. Rationalizing a pharmacological approach on the amyloid precursor protein metabolism
48. Ionic and signal transduction alterations in Alzheimer's disease: Relevance of studies in peripheral cells
49. Protein kinase C activation increases release of secreted amyloid precursor protein without decreasing Abeta production in human primary neuron cultures
50. Constitutitve overactivation of protein kinase C in guinea pig brain increases alpha-secretory APP processing without decreasing beta-amyloid generation
51. Second messenger systems in brains of patients with Parkinson's or Huntington's disease
52. Amyotrophic lateral sclerosis
53. A role for amplified PKC activity in the pathogenesis of amyotrophic lateral sclerosis
54. Decrease of protein kinase C in the spinal motor neurons of amyotrophic lateral sclerosis
55. A novel neuroprotective mechanism of riluzole: Direct inhibition of protein kinase C
56. PKC signaling in the brain: Molecular transduction of mood stabilization in the treatment of manicdepressive illness
57. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains
58. Increased membrane-associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients
59. Increased association of brain protein kinase C with the receptor for activated C kinase-1 (RACK1) in bipolar affective disorder
60. Altered brain protein kinase C in depression: A post-mortem study
61. Increased inhibitory activity of protein kinase C on the serotonin transporter in OCD
62. Phorbol ester binding in human brain: Characterization, regional distribution, age-correlation and alterations in Parkinson's disease
63. New insights into the regulation of PKC and novel phorbol ester receptors
64. The potential for isoenzyme-selective modulation of PKC
65. Enzymatic rationale and preclinical support for a potent PKC beta inhibitor in cancer therapy
66. Anchoring proteins for PKC: A means for isoenzyme selectivity
67. Peptide modulators of proteinprotein interactions in intracellular signaling
68. C2-region-derived peptides of beta protein kinase C regulate cardiac calcium channels
69. An inhibitory fragment derived from εPKC prevents enhancement of NGF responses by ethanol and phorbol esters
70. Protein kinase C ε mediated up regulation of N-type calcium channels by ethanol
71. Key role for the isoform of PKC in painful alcoholic neuropathy in the rat
72. Protein kinase Cδ mediated ethanol-induced up-regulation of L-Type calcium channels
73. Molecular transporter for peptides: Delivery of a cardioprotective ePKC agonist peptide into cells and intact ischemic heart using a transporter system, R7
74. Opposing cardioprotective actions and parallel hypertrophic effects of δ and εPKC
75. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression
76. Identification of PKC-isoformspecific biological actions using pharmacological approaches
77. Recent advances in the discovery of protein kinase C modulators based on the structures of natural protein kinase C activators
78. Localization, anchoring and functions of PKC isozymes in the heart
79. Cardiotrophic effect of PKCε: Analysis by in vivo modulation of PKCε translocation
80. Ischemic preconditioning: From basic mechanisms to clinical applications
81. Sustained in vivo cardiac protection by a rationally designed peptide that causes protein kinase C translocation
82. Evidence from cultured rat cortical neurons of differences in the mechanisms of ischemic preconditioning of brain and heart
83. Rapid preconditioning neuroprotection following anoxia in hippocampal slices: Role of the K+ ATP channel and protein kinase C
84. Rapid decline in PKCγ levels in the synaptosomal fraction of rat hippocampus after ischemic preconditioning
85. Protein kinases and phosphorylation in neurological disorders and cell death
86. Protein kinases as mediators of phosphoinositide 3-kinase signaling
87. Induction of PKC delta subspecies in neurons and microglia after transient global brain ischemia
88. Clinical trials with neuroprotective drugs in acute ischemic stroke: Are we doing the right thing?